SynthesisCancer2008
Breast cancer adjuvant chemotherapy dosing in obese patients: dissemination of information from clinical trials to clinical practice.
Synthesis in Cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies.Annals of oncology : official journal of the European Society for Medical Oncology · 2014Pooled it
- The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436).Journal of geriatric oncology · 2018Trial
- Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancer.Journal of the National Cancer Institute · 2026Article
- Initial chemotherapy dose reductions and subsequent treatment delivery in stage I-IIIA breast cancer.Cancer · 2026Article
- Understanding the association between body mass index and chemotherapy dose reductions in women treated for stage I-IIIA breast cancer.NPJ breast cancer · 2025Article
- Patient factors and modifications to intended chemotherapy for women with Stages I-IIIA breast cancer.International journal of cancer · 2025Article
- Assessment of breast cancer chemotherapy dose reduction in an integrated healthcare delivery system.Breast cancer research and treatment · 2024Article
- Too Much, Too Little, or Just Right? Obesity and Dosing of Targeted Therapies in Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Body mass index and patient-reported function, quality of life and treatment toxicity in women receiving adjuvant chemotherapy for breast cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study.The Lancet. Oncology · 2016Observational
- Impact of obesity on chemotherapy management and outcomes in women with gynecologic malignancies.Gynecologic oncology · 2015Review
- Obesity Correlation With Metastases Development and Response to First-Line Metastatic Chemotherapy in Breast Cancer.Clinical Medicine Insights. Oncology · 2015Article
- Article
- Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women.Medical oncology (Northwood, London, England) · 2014Article
- Clinical management of obese patients with cancer.Nature reviews. Clinical oncology · 2013Review
- Chemotherapy dosing in overweight and obese patients with cancer.Nature reviews. Clinical oncology · 2013Review
- Association between parity and obesity in Mexican and Mexican-American women: findings from the Ella binational breast cancer study.Journal of immigrant and minority health · 2013Article
- Pre-diagnosis body mass index and survival after breast cancer in the After Breast Cancer Pooling Project.Breast cancer research and treatment · 2012Article
- The impact of obesity on receipt of adjuvant chemotherapy for breast cancer in the National Comprehensive Cancer Network (NCCN) centers.Breast cancer research and treatment · 2011Article
- Obesity is an independent predictor of poor survival in metastatic breast cancer: retrospective analysis of a patient cohort whose treatment included high-dose chemotherapy and autologous stem cell support.International journal of breast cancer · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundSubstantial variation in adjuvant breast cancer chemotherapy dosing in obese women suggests that there is uncertainty about optimal practices. The purpose of this study was to investigate variations in dose determinations in clinical trial protocols and publications over the last 3 decades as potential sources of this uncertainty.
methodsThe National Cancer Institute database was used to identify protocols of breast cancer adjuvant chemotherapy conducted by cooperative groups between 1970-2000, and these protocols were then obtained directly from the cooperative groups. Dose determinations were categorized in each protocol and in published reports from each clinical trial. Fisher exact tests were used to compare the proportions of protocols that used full weight-based doses over time.
resultsProtocol-specified chemotherapy dosing was obtained for all of 44 eligible trials. A significant increase was identified in the use of full weight-based doses in the later time period compared with the earlier (P = .004; 2-sided Fisher exact test). A notable exception was 1 cooperative group that continues to require dose limitations for doxorubicin and cyclophosphamide in patients with a body surface area of more than 2.0 m(2). Regardless of publication date, published reports of clinical trials rarely provide information on use of full or limited weight-based doses.
conclusionsVariations in dose determinations among clinical trial protocols and lack of information on use of full weight-based doses in most publications are 2 likely sources of variation in chemotherapy dosing in obese women. Developing consensus and disseminating information on optimal chemotherapy dosing will likely reduce such variation and may improve survival among obese patients with breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.